Disease Detail

ID DOID:3068
Name glioblastoma multiforme
Definition An astrocytoma characterized by the presence of small areas of necrotizing tissue that is surrounded by anaplastic cells as well as the presence of hyperplastic blood vessels, and that has_material_basis_in abnormally proliferating cells derives_from multiple cell types including astrocytes and oligondroctyes.
Source DiseaseOntology.org
Alt Ids DOID:3075 DOID:3080
Path disease disease of cellular proliferation cancer organ system cancer nervous system cancer central nervous system cancer astrocytoma glioblastoma multiforme

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown EMD 1214063 glioblastoma multiforme not applicable detail...
PTEN wild-type 2-Methoxyestradiol glioblastoma multiforme sensitive detail...
PTEN loss CCT128930 glioblastoma multiforme sensitive detail...
Unknown unknown Regorafenib glioblastoma multiforme not applicable detail...
SRC positive Dasatinib glioblastoma multiforme sensitive detail...
TP53 mutant Adavosertib + Radiotherapy glioblastoma multiforme sensitive detail...
Unknown unknown Sunitinib glioblastoma multiforme no benefit detail...
MSH6 T1219I Temozolomide glioblastoma multiforme resistant detail...
Unknown unknown Enzastaurin glioblastoma multiforme not applicable detail...
Unknown unknown Bevacizumab glioblastoma multiforme not applicable detail...
Unknown unknown Ponatinib glioblastoma multiforme not applicable detail...
PTEN loss PF-04691502 glioblastoma multiforme sensitive detail...
FGFR3-TACC3 U0126 glioblastoma multiforme sensitive detail...
FGFR3 over exp U0126 glioblastoma multiforme sensitive detail...
Unknown unknown LYS6KAKT1 glioblastoma multiforme not applicable detail...
Unknown unknown CC-115 glioblastoma multiforme not applicable detail...
Unknown unknown BMS-906024 glioblastoma multiforme not applicable detail...
IDH1 R132H Temozolomide + Vandetanib glioblastoma multiforme sensitive detail...
Unknown unknown Temozolomide + Vandetanib glioblastoma multiforme not applicable detail...
PTEN negative Temozolomide + Vandetanib glioblastoma multiforme no benefit detail...
Unknown unknown Tanibirumab glioblastoma multiforme not applicable detail...
Unknown unknown GSK1838705A glioblastoma multiforme not applicable detail...
FGFR3-TACC3 Erdafitinib glioblastoma multiforme predicted - sensitive detail...
Unknown unknown MPS1-IN-3 + Vincristine glioblastoma multiforme not applicable detail...
IDH1 mutant Bevacizumab + Lomustine glioblastoma multiforme predicted - sensitive detail...
Unknown unknown PRN1371 glioblastoma multiforme not applicable detail...
Unknown unknown COG112 glioblastoma multiforme not applicable detail...
Unknown unknown LB-100 glioblastoma multiforme not applicable detail...
Unknown unknown Imetelstat glioblastoma multiforme not applicable detail...
Unknown unknown Bortezomib + Vorinostat glioblastoma multiforme not applicable detail...
Unknown unknown Marizomib + Vorinostat glioblastoma multiforme not applicable detail...
Unknown unknown Bortezomib + Panobinostat glioblastoma multiforme not applicable detail...
Unknown unknown Marizomib + Panobinostat glioblastoma multiforme not applicable detail...
Unknown unknown SEN-450 + Temozolomide glioblastoma multiforme not applicable detail...
PTEN loss PKI-402 glioblastoma multiforme sensitive detail...
IDH1 mutant N/A glioblastoma multiforme not applicable detail...
ATRX loss Doxorubicin glioblastoma multiforme sensitive detail...
ATRX loss Irinotecan glioblastoma multiforme sensitive detail...
ATRX loss Topotecan glioblastoma multiforme sensitive detail...
STAG2 N357fs Olaparib glioblastoma multiforme sensitive detail...
STAG2 N357fs Veliparib glioblastoma multiforme sensitive detail...
STAG2 N357fs Rucaparib glioblastoma multiforme sensitive detail...
STAG2 S653* Olaparib glioblastoma multiforme sensitive detail...
STAG2 N357fs Olaparib + Temozolomide glioblastoma multiforme sensitive detail...
STAG2 N357fs Camptothecin + Olaparib glioblastoma multiforme sensitive detail...
STAG2 S653* Camptothecin glioblastoma multiforme sensitive detail...
PTEN V54fs XL147 glioblastoma multiforme sensitive detail...
Unknown unknown Valproic acid glioblastoma multiforme no benefit detail...
Unknown unknown Ad-RTS-IL-12 plus AL glioblastoma multiforme not applicable detail...
Unknown unknown Selinexor glioblastoma multiforme not applicable detail...
MET over exp Altiratinib glioblastoma multiforme predicted - sensitive detail...
MET positive Altiratinib + Bevacizumab glioblastoma multiforme sensitive detail...
MET positive Altiratinib glioblastoma multiforme predicted - sensitive detail...
TP53 mutant Adavosertib glioblastoma multiforme sensitive detail...
NOTCH1 positive LY3039478 glioblastoma multiforme sensitive detail...
SRC positive Si306 glioblastoma multiforme sensitive detail...
SRC positive Radiotherapy + Si306 glioblastoma multiforme sensitive detail...
Unknown unknown Abemaciclib glioblastoma multiforme not applicable detail...
PTEN loss A66 glioblastoma multiforme resistant detail...
Unknown unknown Dovitinib glioblastoma multiforme not applicable detail...
Unknown unknown Cediranib + Lomustine glioblastoma multiforme not applicable detail...
Unknown unknown Cediranib + Gefitinib glioblastoma multiforme not applicable detail...
Unknown unknown ST-11 glioblastoma multiforme not applicable detail...
Unknown unknown BLZ945 glioblastoma multiforme not applicable detail...
Unknown unknown BLZ945 + Buparlisib glioblastoma multiforme not applicable detail...
Unknown unknown Buparlisib glioblastoma multiforme no benefit detail...
PTEN loss BLZ945 glioblastoma multiforme no benefit detail...
TP53 loss BLZ945 glioblastoma multiforme sensitive detail...
NOTCH1 positive Radiotherapy + RO4929097 + Temozolomide glioblastoma multiforme sensitive detail...
Unknown unknown Radiotherapy + Temsirolimus glioblastoma multiforme no benefit detail...
PTEN loss LY3023414 glioblastoma multiforme sensitive detail...
Unknown unknown MGCD516 glioblastoma multiforme not applicable detail...
RB1 positive Palbociclib glioblastoma multiforme predicted - sensitive detail...
RB1 inact mut Palbociclib glioblastoma multiforme resistant detail...
Unknown unknown Durvalumab glioblastoma multiforme not applicable detail...
CDKN2A pos RB1 inact mut Palbociclib glioblastoma multiforme resistant detail...
CDKN2A del Palbociclib glioblastoma multiforme sensitive detail...
Unknown unknown SL-701 glioblastoma multiforme not applicable detail...
Unknown unknown Bevacizumab + SL-701 glioblastoma multiforme not applicable detail...
Unknown unknown Pexidartinib glioblastoma multiforme not applicable detail...
KIT amp PDGFRA amp DCC-2618 glioblastoma multiforme sensitive detail...
PTEN mutant TP53 mutant Navitoclax + ONC201 glioblastoma multiforme sensitive detail...
BRAF V600E PD-0325901 glioblastoma multiforme decreased response detail...
BRAF V600E PLX4720 glioblastoma multiforme decreased response detail...
Unknown unknown BI2536 glioblastoma multiforme sensitive detail...
BRAF V600E BI2536 glioblastoma multiforme sensitive detail...
Unknown unknown BI2536 + PD-0325901 glioblastoma multiforme not applicable detail...
BRAF V600E BI2536 + PLX4720 glioblastoma multiforme sensitive detail...
Unknown unknown GDC-0152 glioblastoma multiforme not applicable detail...
Unknown unknown PRX177561 + Sunitinib glioblastoma multiforme not applicable detail...
Unknown unknown Bevacizumab + PRX177561 glioblastoma multiforme not applicable detail...
PTEN loss GDC-0084 glioblastoma multiforme sensitive detail...
PTEN inact mut SAR245409 glioblastoma multiforme sensitive detail...
PTEN inact mut SF1126 glioblastoma multiforme sensitive detail...
IDH2 R140Q Enasidenib glioblastoma multiforme predicted - sensitive detail...
IDH2 R172K Enasidenib glioblastoma multiforme predicted - sensitive detail...
Unknown unknown Alisertib glioblastoma multiforme not applicable detail...
Unknown unknown SA16 glioblastoma multiforme not applicable detail...
Unknown unknown MP7 glioblastoma multiforme no benefit detail...
Unknown unknown Alisertib + MP7 glioblastoma multiforme not applicable detail...
Unknown unknown G-TPP + Navitoclax glioblastoma multiforme not applicable detail...
Unknown unknown G-TPP + Obatoclax glioblastoma multiforme not applicable detail...
Unknown unknown G-TPP + WEHI-539 glioblastoma multiforme not applicable detail...
Unknown unknown G-TPP + Venetoclax glioblastoma multiforme not applicable detail...
Unknown unknown A-1210477 + G-TPP glioblastoma multiforme not applicable detail...
ERBB2 positive HER2 CAR-T cells glioblastoma multiforme sensitive detail...
BRAF V600E Ulixertinib glioblastoma multiforme sensitive detail...
Unknown unknown A-966492 + Radiotherapy + Topotecan glioblastoma multiforme not applicable detail...
Unknown unknown SR9009 glioblastoma multiforme not applicable detail...
Unknown unknown BGB-5777 glioblastoma multiforme not applicable detail...
IDH2 mutant N/A glioblastoma multiforme not applicable detail...
Unknown unknown CID613034 glioblastoma multiforme not applicable detail...
Unknown unknown JR-AB2-011 glioblastoma multiforme not applicable detail...
Unknown unknown Everolimus + Vorolanib glioblastoma multiforme not applicable detail...
BRAF V600E Dabrafenib + Trametinib glioblastoma multiforme predicted - sensitive detail...
ATM positive AZD1390 glioblastoma multiforme sensitive detail...
TP53 mutant AZD1390 glioblastoma multiforme sensitive detail...
Unknown unknown VAL-083 glioblastoma multiforme not applicable detail...
Unknown unknown Adavosertib glioblastoma multiforme not applicable detail...
Unknown unknown DCVax-L glioblastoma multiforme not applicable detail...
Unknown unknown Gliovac + Sargramostim glioblastoma multiforme not applicable detail...
Unknown unknown WT2725 glioblastoma multiforme not applicable detail...
MET positive Ningetinib glioblastoma multiforme sensitive detail...
Unknown unknown PVSRIPO glioblastoma multiforme not applicable detail...
Unknown unknown Iniparib + Radiotherapy + Temozolomide glioblastoma multiforme not applicable detail...
IDH1 wild-type PTEN mutant Pembrolizumab glioblastoma multiforme resistant detail...
IDH1 wild-type PTEN mutant Nivolumab glioblastoma multiforme resistant detail...
BRAF mutant IDH1 wild-type Pembrolizumab glioblastoma multiforme predicted - sensitive detail...
BRAF mutant IDH1 wild-type Nivolumab glioblastoma multiforme predicted - sensitive detail...
IDH1 wild-type PTPN11 mutant Pembrolizumab glioblastoma multiforme predicted - sensitive detail...
IDH1 wild-type PTPN11 mutant Nivolumab glioblastoma multiforme predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00054496 Phase II Erlotinib Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme Unknown status
NCT00301418 Phase Ib/II Erlotinib Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma Completed
NCT00492687 Phase II Carboplatin Temozolomide Tamoxifen Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas Unknown status
NCT00669669 Phase Ib/II O6-benzylguanine Carmustine + Filgrastim + Plerixafor + Temozolomide Dose-Intensive Chemotherapy in Combination With Chemoprotected Autologous Stem Cells in Treating Patients With Malignant Gliomas Active, not recruiting
NCT00906516 Phase II 81C6 + Bevacizumab Neuradiab Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme Unknown status
NCT00968240 Phase I Bevacizumab Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab) Completed
NCT00998010 Phase II Bortezomib + Temozolomide Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma Completed
NCT01052363 Phase I Bevacizumab + Fosbretabulin OXC401-PO1s/WVU 1309 - A Pilot Study of Fosbretabulin With Bevacizumab in Recurrent High-Grade Gliomas Withdrawn
NCT01067469 Phase II Bevacizumab Bevacizumab + Lomustine Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM) Completed
NCT01107522 Phase I Carboxyamidotriazole Orotate + Temozolomide Carboxyamidotriazole Orotate Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas Active, not recruiting
NCT01112527 Phase II Dacomitinib PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma Completed
NCT01130077 Phase I Poly ICLC A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction With Poly-ICLC in Pediatric Gliomas Recruiting
NCT01140568 Phase II Nilotinib Study of Platelet Derived Growth Factor Receptor (PDGFR) in Recurrent Malignant Gliomas Terminated
NCT01149850 Phase II Bevacizumab + Temozolomide Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma Active, not recruiting
NCT01177397 Phase Ib/II CC-223 Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma Completed
NCT01238237 Phase I Cetuximab Super-Selective Intraarterial Cerebral Infusion of Cetuximab for the Treatment of Recurrent Glioblastoma Multiforme and Anaplastic Astrocytoma Completed
NCT01260506 Phase Ib/II Bevacizumab + VB-111 Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme Unknown status
NCT01266031 Phase Ib/II Bevacizumab + Vorinostat Bevacizumab Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma Completed
NCT01269424 Phase I O6-benzylguanine + Temozolomide O6-Benzylguanine and Temozolomide With MGMTP140K Genetically Modified Blood Stem Cells in Untreated Glioblastoma Terminated
NCT01269853 Phase Ib/II Bevacizumab Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA Recruiting
NCT01290263 Phase Ib/II Bevacizumab + Trebananib Trebananib Amgen 386 for Recurrent Glioblastoma Completed
NCT01331291 Phase II Bosutinib Bosutinib in Adult Patients With Recurrent Glioblastoma Completed
NCT01331616 Phase I Bevacizumab Optic Neuropathy in 10 Patients With Glioblastoma Receiving Bevacizumab Unknown status
NCT01339039 Phase I Bevacizumab + Plerixafor Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma Terminated
NCT01349660 Phase Ib/II Bevacizumab + Buparlisib Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme Active, not recruiting
NCT01386710 Phase Ib/II Bevacizumab + Carboplatin Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma Suspended
NCT01421524 Phase I CC-122 Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma Active, not recruiting
NCT01434602 Phase Ib/II Everolimus + Sorafenib Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas Recruiting
NCT01435395 Phase I Bevacizumab + Bortezomib + Temozolomide Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme Completed
NCT01473901 Phase I Buparlisib + Temozolomide A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed
NCT01478178 Phase Ib/II VAL-083 Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma or Progressive Secondary Brain Tumor Completed
NCT01478321 Phase II Bevacizumab + Temozolomide Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas Active, not recruiting
NCT01508117 Phase II Axitinib Phase II Axitinib (AG-013736) in Elderly Glioblastoma Multiforme (GBM) Patients Terminated
NCT01526837 Phase I Bevacizumab Bevacizumab (Avastin) Into the Tumor Resection Cavity in Subjects With Glioblastoma Multiforme at First Recurrence Terminated
NCT01576666 Phase Ib/II Buparlisib + Sonidegib Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors Completed
NCT01591577 Phase II Lapatinib + Temozolomide Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Newly-Diagnosed Glioblastoma Multiforme Active, not recruiting
NCT01607905 Phase I Selinexor Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer Completed
NCT01621542 Phase I WT2725 Clinical Study of WT2725 in Patients With Advanced Malignancies Completed
NCT01672463 Phase I OKN-007 Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients Recruiting
NCT01721577 Phase Ib/II AXL1717 Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas Unknown status
NCT01730950 Phase II Bevacizumab Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma Active, not recruiting
NCT01753713 Phase II Dovitinib Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma Completed
NCT01756352 Phase II Bevacizumab FET-PET for Evaluation of Response of Recurrent GBM to Avastin Completed
NCT01788280 Phase I Bevacizumab Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab Withdrawn
NCT01790503 Phase Ib/II Pexidartinib Temozolomide A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma Active, not recruiting
NCT01800695 Phase I Temozolomide Depatuxizumab mafodotin Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme Completed
NCT01811498 Phase Ib/II Bevacizumab Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM Recruiting
NCT01814813 Phase II Bevacizumab Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery Active, not recruiting
NCT01837862 Phase Ib/II Carboplatin + Mebendazole + Temozolomide + Vincristine Bevacizumab + Irinotecan + Mebendazole A Phase I/II Study of Mebendazole for the Treatment of Pediatric Gliomas Recruiting
NCT01849146 Phase I Adavosertib + Temozolomide WEE1 Inhibitor MK-1775, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme Recruiting
NCT01860638 Phase III Bevacizumab Lomustine A Comparison of Continuous Avastin (Bevacizumab) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Patients With Glioblastoma Completed
NCT01870726 Phase Ib/II Buparlisib + Capmatinib Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Gliobastoma Terminated
NCT01884740 Phase Ib/II Bevacizumab + Cetuximab Phase I/II Trial Of Super-Selective Intraarterial Infusion Of Erbitux and Bevacizumab For Treatment Of Relapsed/Refractory Intracranial Glioma In Patients Under 22 Years Of Age Recruiting
NCT01891747 Phase Ib/II Bevacizumab + Temozolomide A Phase I/II Study of High-dose L-methylfolate in Combination With Temozolomide and Bevacizumab in Recurrent High Grade Glioma Active, not recruiting
NCT01894061 Phase II Bevacizumab NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma Recruiting
NCT01903330 Phase II Bevacizumab Cyclophosphamide Sargramostim ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme Recruiting
NCT01904123 Phase I WP1066 A Phase I Trial of WP1066 Recruiting
NCT01925573 Phase I Bevacizumab NOVOTTF-100A+ Bevacizumab+ Hypofractionated Stereotactic Irradiation Bevacizumab-Naive Recurrent Glioblastoma (GCC 1344) Recruiting
NCT01931098 Phase II Pazopanib + Topotecan Phase II Pazopanib Plus Topotecan for Recurrent Glioblastoma Multiforme (GBM) Active, not recruiting
NCT01933815 Phase Ib/II Bevacizumab TPI 287 Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma Suspended
NCT01934361 Phase Ib/II Buparlisib + Lomustine Buparlisib + Carboplatin Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme Completed
NCT01954576 Phase II NovoTTF Therapy in Treating Patients With Recurrent Glioblastoma Multiforme Recruiting
NCT01975701 Phase II BGJ398 A Phase 2 Study of BGJ398 in Patients With Recurrent GBM Completed
NCT01977677 Phase Ib/II Temozolomide Plerixafor Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma Completed
NCT01986348 Phase II Selinexor Phase 2 Study of Selinexor (KPT-330) in Patients With Recurrent Glioblastoma After Failure of Radiation and Temozolomide Active, not recruiting
NCT01989052 Phase Ib/II Lomustine Carboxyamidotriazole Orotate Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma Terminated
NCT01999270 Phase I Bevacizumab + Irinotecan Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors Completed
NCT02010606 Phase I Bevacizumab Temozolomide Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma Active, not recruiting
NCT02017717 Phase III Nivolumab Bevacizumab Ipilimumab + Nivolumab A Randomized Study of Nivolumab Versus Bevacizumab and a Safety Study of Nivolumab in Adult Subjects With Recurrent Glioblastoma (GBM) (CheckMate 143) Active, not recruiting
NCT02026271 Phase I Ad-RTS-IL-12 plus AL A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma Active, not recruiting
NCT02038699 Phase Ib/II ONC201 A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer Withdrawn
NCT02047214 Phase II Bevacizumab + Paclitaxel Safety and Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy Terminated
NCT02052778 Phase Ib/II TAS-120 A Study of TAS-120 in Patients With Advanced Solid Tumors Recruiting
NCT02067156 Phase II mipsagargin Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma Completed
NCT02101905 Phase I Lapatinib Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma Recruiting
NCT02120287 Phase II Bevacizumab Border Zone Stereotactic Radiosurgery With Bevacizumab in Patients With Glioblastoma Multiforme Completed
NCT02133183 Phase I Sapanisertib TORC1/2 Inhibitor INK128 Before and After Surgery in Treating Patients With Recurrent Glioblastoma Recruiting
NCT02137759 Phase II Vorinostat Temozolomide MRSI to Predict Response to RT/TMZ and Vorinostat in GBM Recruiting
NCT02146066 Expanded access DCVax-L Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221 Available
NCT02152982 Phase II Veliparib Temozolomide Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Active, not recruiting
NCT02157103 Phase II Bevacizumab A Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma Completed
NCT02179086 Phase II Temozolomide Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Recruiting
NCT02197169 Phase I DNX-2401 DNX-2401 + interferon gamma DNX-2401 With Interferon Gamma (IFN-gamma) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors (TARGET-I) Completed
NCT02238496 Phase II Perifosine + Temsirolimus Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas Active, not recruiting
NCT02285959 Phase I Bevacizumab Super-Selective Intraarterial Intracranial Infusion of Bevacizumab (Avastin) for Glioblastoma Multiforme Recruiting
NCT02311582 Phase Ib/II Pembrolizumab MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas Recruiting
NCT02311920 Phase I Temozolomide Nivolumab Ipilimumab Temozolomide in Combination With Ipilimumab and/or Nivolumab in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma Active, not recruiting
NCT02315534 Phase Ib/II Napabucasin Temozolomide A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma Completed
NCT02327078 Phase Ib/II Epacadostat + Nivolumab A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers Active, not recruiting
NCT02336165 Phase II Durvalumab Bevacizumab + Durvalumab Phase 2 Study of MEDI4736 in Patients With Glioblastoma Active, not recruiting
NCT02337491 Phase II Pembrolizumab Bevacizumab + Pembrolizumab Pembrolizumab +/- Bevacizumab for Recurrent GBM Active, not recruiting
NCT02340156 Phase II SGT-53 Temozolomide Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma Recruiting
NCT02342379 Phase II Bevacizumab + Evofosfamide TH-302 in Combination With Bevacizumab for Glioblastoma Active, not recruiting
NCT02343406 Phase II Lomustine Depatuxizumab mafodotin Temozolomide ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Recruiting
NCT02343549 Phase II Bevacizumab + Temozolomide LCI-NEU-NOV-001 Study of a Device Worn on the Head in Combination With Chemo to Treat Brain Cancer Recruiting
NCT02345824 Phase I Ribociclib Early-Phase Study to Assess Inhibitor LEE011 in Patients With Recurrent Glioblastoma or Anaplastic Glioma Active, not recruiting
NCT02348255 Phase II Bevacizumab + Carmustine NovoTTF-100A in Combination With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse Withdrawn
NCT02365662 Phase I ABBV-221 A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor Terminated
NCT02386826 Phase I Bevacizumab + Capmatinib INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme Recruiting
NCT02414165 Phase II Bevacizumab Lomustine Toca 511 + Toca FC Temozolomide P2/3 Randomized Study of Toca 511 & Toca FC Versus SOC in Subjects Undergoing Surgery for Recurrent GBM/AA (Toca5) Active, not recruiting
NCT02423525 Phase I Afatinib Safety Study of Afatinib for Brain Cancer Recruiting
NCT02442297 Phase I HER2 sensitized T-cells T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With Glioblastoma Recruiting
NCT02465268 Phase II pp65 Dendritic Cell Vaccine + Sargramostim Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme (ATTAC-II) Recruiting
NCT02478164 Phase II Ponatinib Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma Completed
NCT02498665 Phase I DSP-7888 A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies Active, not recruiting
NCT02510950 Phase I Sargramostim Poly ICLC Temozolomide Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma Terminated
NCT02511405 Phase III Bevacizumab VB-111 A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE) Completed
NCT02521090 Phase Ib/II EGFRBi-armed autologous activated T cells EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory Glioblastoma Withdrawn
NCT02525692 Phase II ONC201 Oral ONC201 in Adult Recurrent Glioblastoma Recruiting
NCT02526017 Phase I Cabiralizumab Nivolumab Study of FPA008 in Combination With Nivolumab in Patients With Selected Advance Cancers Active, not recruiting
NCT02530502 Phase Ib/II Temozolomide Pembrolizumab Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma Active, not recruiting
NCT02573324 Phase II Depatuxizumab mafodotin Temozolomide A Study of ABT-414 in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification Recruiting
NCT02586857 Phase Ib/II Acalabrutinib A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM) Active, not recruiting
NCT02605746 Phase I Ceritinib Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS Metastasis Unknown status
NCT02607124 Phase Ib/II Ribociclib Administration of Ribociclib Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG) Active, not recruiting
NCT02617589 Phase III Nivolumab Temozolomide Study of Nivolumab Versus Temozolomide, Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) (CheckMate 498) Recruiting
NCT02619864 Phase Ib/II Vistusertib mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme Active, not recruiting
NCT02626364 Phase II Crenolanib Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification Recruiting
NCT02648633 Phase I Nivolumab + Valproic acid Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma Terminated
NCT02663271 Phase II Bevacizumab TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma Recruiting
NCT02667587 Phase II Temozolomide Nivolumab + Temozolomide Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer). Active, not recruiting
NCT02717962 Phase II VAL-083 Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Recurrent Glioblastoma Recruiting
NCT02743078 Phase II Bevacizumab Optune Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma Active, not recruiting
NCT02754362 Phase II Poly ICLC Bevacizumab A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma Active, not recruiting
NCT02766699 Phase I EGFR(V)-EDV-Dox A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent Glioblastoma Multiforme (GBM) (CerebralEDV) Recruiting
NCT02768389 Phase I Bevacizumab Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma Completed
NCT02780024 Phase II Metformin Metformin, Neo-adjuvant Temozolomide and Hypo- Accelerated Radiotherapy Followed by Adjuvant TMZ in Patients With GBM Recruiting
NCT02783300 Phase I GSK3326595 Dose Escalation Study of GSK3326595 in Subjects With Solid Tumors and Non-Hodgkin's Lymphoma Recruiting
NCT02798406 Phase II DNX-2401 + Pembrolizumab Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects (CAPTIVE) Active, not recruiting
NCT02800486 Phase II Cetuximab Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA Recruiting
NCT02829723 Phase Ib/II BLZ945 BLZ945 + PDR001 Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors Recruiting
NCT02844439 Phase II XL647 Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma Active, not recruiting
NCT02852655 Phase 0 Pembrolizumab A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma Active, not recruiting
NCT02858895 Phase II MDNA55 Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma Active, not recruiting
NCT02861898 Phase Ib/II Cetuximab + Mannitol Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma Recruiting
NCT02871843 Phase I RRx-001 + Temozolomide Phase 1 Two Part Dose Escalation Trial of RRx-001 + Radiation + Temozolomide and RRx-001 + Temozolomide Post-RT In Newly Diagnosed Glioblastoma and Anaplastic Gliomas (G-FORCE-1) Active, not recruiting
NCT02876003 Phase II mipsagargin Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma Withdrawn
NCT02885324 Phase II Cabozantinib Pilot Study of Cabozantinib for Recurrent or Progressive High-Grade Glioma in Children Recruiting
NCT02928575 Phase II Sunitinib + Temozolomide Combining Sunitinib, Temozolomide and Radiation to Treat Patients Diagnosed With Glioblastoma Unknown status
NCT02942264 Phase Ib/II TG02 Temozolomide + TG02 TG02 Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of TG02 Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma Recruiting
NCT02968940 Phase II Avelumab Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma Active, not recruiting
NCT02974621 Phase II Bevacizumab Cediranib + Olaparib Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma Active, not recruiting
NCT02977780 Phase II CC-115 Abemaciclib + Temozolomide Temozolomide Neratinib + Temozolomide INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) Recruiting
NCT02981940 Phase II Abemaciclib A Study of Abemaciclib in Recurrent Glioblastoma Active, not recruiting
NCT03014804 Phase II DCVax-L DCVax-L + Nivolumab Dendritic Cell-Autologous Lung Tumor Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma Not yet recruiting
NCT03018288 Phase II Pembrolizumab + Temozolomide Pembrolizumab + Temozolomide + Vitespen Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM) Recruiting
NCT03027388 Phase I LB-100 Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma Recruiting
NCT03047473 Phase II Avelumab Avelumab in Patients With Newly Diagnosed Glioblastoma Multiforme (SEJ) Recruiting
NCT03107780 Phase I AMG 232 MDM2 Inhibitor AMG-232 in Treating Patients With Recurrent or Newly Diagnosed Glioblastoma Recruiting
NCT03128047 Phase I Bevacizumab + Temozolomide HUMC 1612: Optune NovoTTF-200A System Recruiting
NCT03139916 Phase II Bavituximab + Temozolomide Phase II Clinical Trial of Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma Active, not recruiting
NCT03149003 Phase II Bevacizumab + DSP-7888 Bevacizumab A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy (WIZARD201G) Recruiting
NCT03150862 Phase Ib/II Pamiparib Pamiparib + Temozolomide A Study Assessing BGB-290 With Radiation and/or Temozolomide (TMZ) in Subjects With Newly Diagnosed or Recurrent Glioblastoma Recruiting
NCT03174197 Phase Ib/II Atezolizumab + Temozolomide Atezolizumab (aPDL1) + Temozolomide and Radiation for Newly Diagnosed Glioblastoma (GBM) Recruiting
NCT03197506 Phase II Pembrolizumab + Temozolomide Pembrolizumab Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma Suspended
NCT03216499 Phase II PT2385 HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma Active, not recruiting
NCT03234712 Phase I ABBV-321 A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR) or Its Ligands Recruiting
NCT03250299 Phase I BAL101553 Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Active, not recruiting
NCT03277638 Phase Ib/II Pembrolizumab Laser Interstitial Thermotherapy Combined With Checkpoint Inhibitor for Recurrent Glioblastoma Recruiting
NCT03295396 Phase II ONC201 ONC201 in Adults With Recurrent High-grade Glioma Recruiting
NCT03296696 Phase I AMG 596 Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma Recruiting
NCT03332355 Phase I PAC-1 + Temozolomide Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2 Recruiting
NCT03341806 Phase I Avelumab Avelumab With Laser Interstitial Therapy for Recurrent Glioblastoma Recruiting
NCT03347617 Phase II Pembrolizumab Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Brain Tumors From Melanoma and Glioblastoma Recruiting
NCT03367715 Phase II Ipilimumab + Nivolumab Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma Recruiting
NCT03382977 Phase I VBI-1901 Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects Recruiting
NCT03405792 Phase II Pembrolizumab + Temozolomide Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP) Recruiting
NCT03422094 Phase I Ipilimumab + NeoVax + Nivolumab NeoVax + Nivolumab Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma Recruiting
NCT03423628 Phase I AZD1390 A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer Recruiting
NCT03425292 Phase I Temozolomide Ipilimumab + Nivolumab Nivolumab A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer Recruiting
NCT03426891 Phase I Pembrolizumab + Temozolomide + Vorinostat Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma Recruiting
NCT03430791 Phase II Ipilimumab + Nivolumab Nivolumab Trial of Combination TTF(Optune), Nivolumab Plus/Minus Ipilimumab for Bevacizumab-naïve, Recurrent Glioblastoma Recruiting
NCT03452579 Phase II Bevacizumab + Nivolumab Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM Recruiting
NCT03452930 Phase I Tinostamustine EDO-S101 for MGMT Unmethylated Glioblastoma (nGBM) Recruiting
NCT03463265 Phase II Lomustine + Nab-Rapamycin Nab-Rapamycin Nab-Rapamycin + Temozolomide Bevacizumab + Nab-Rapamycin ABI-009 (Nab-Rapamycin) in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma Recruiting
NCT03491683 Phase Ib/II Cemiplimab + INO-5401 + INO-9012 + Temozolomide INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) Active, not recruiting
NCT03493932 Phase I Nivolumab + Relatlimab Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade Recruiting
NCT03514069 Phase I Ruxolitinib Ruxolitinib + Temozolomide Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma Recruiting
NCT03535350 Phase I Ibrutinib Ibrutinib + Temozolomide Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Recruiting
NCT03596086 Phase Ib/II HSV-Tk + Valacyclovir HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM Recruiting
NCT03603405 Phase Ib/II HSV-Tk HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM Recruiting
NCT03605550 Phase I PTC596 A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma Recruiting
NCT03607643 Phase Ib/II Temozolomide Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Bevacizumab + Cannabidiol + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Bortezomib Bortezomib + Cannabidiol Cannabidiol + Gemcitabine Cannabidiol + Temozolomide Gemcitabine A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies Not yet recruiting
NCT03636477 Phase I Ad-RTS-IL-12 plus AL + Nivolumab A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102 Recruiting
NCT03637764 Phase Ib/II Atezolizumab + Isatuximab Isatuximab Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies Recruiting
NCT03661723 Phase II Bevacizumab Pembrolizumab Bevacizumab + Pembrolizumab Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma Recruiting
NCT03688178 Phase II pp65 Dendritic Cell Vaccine + Temozolomide pp65 Dendritic Cell Vaccine + Temozolomide + Varlilumab DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab (DERIVe) Not yet recruiting
NCT03696355 Phase I GDC-0084 Study of GDC-0084 in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline Gliomas Recruiting
NCT03707457 Phase I Ipilimumab + Nivolumab MK-4166 + Nivolumab Epacadostat + Nivolumab Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma Recruiting
NCT03726515 Phase I CART-EGFRvIII + Pembrolizumab CART-EGFRvIII + Pembrolizumab in GBM Recruiting
NCT03732352 Phase II Osimertinib 18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients With EGFR Activated Recurrent Glioblastoma Recruiting
NCT03743662 Phase II Nivolumab Bevacizumab Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma Recruiting
NCT03782415 Phase Ib/II Temozolomide Ibudilast + Temozolomide Study to Evaluate Ibudilast and TMZ Combo Treatment in Recurrent GBM Recruiting
NCT03797326 Phase II Lenvatinib + Pembrolizumab Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) Recruiting
NCT03893487 Phase I CUDC-907 Fimepinostat in Treating Brain Tumors in Children and Young Adults (PNOC016) Not yet recruiting